Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT M RAMIREZ

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1063512713
CMS profile
3511
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,016.05

75 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,016.05 75

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT M RAMIREZ

NPI 1063512713 · CMS profile ID 3511

Allopathic & Osteopathic Physicians / Allergy & Immunology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063512713?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT M RAMIREZ, NPI 1063512713, CMS profile ID 3511. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063512713?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ROBERT M RAMIREZ, NPI 1063512713, CMS profile ID 3511. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063512713?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ROBERT M RAMIREZ, NPI 1063512713, CMS profile ID 3511, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1063512713?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

75 matching records · $2,016.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 75 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–75 of 75.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $16.5605/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802195333 CMS
Teva Pharmaceuticals USA, Inc. $19.4605/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839623499 CMS
CSL Behring $17.5705/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820235195 CMS
GlaxoSmithKline, LLC. $124.9905/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801609293 CMS
Regeneron Healthcare Solutions, Inc. $26.2204/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809616423 CMS
AstraZeneca Pharmaceuticals LP $24.2504/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829831295 CMS
GlaxoSmithKline, LLC. $1.1504/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802996697 CMS
AstraZeneca Pharmaceuticals LP $124.9904/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829940523 CMS
ALK-Abello, Inc $14.9704/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809210213 CMS
GlaxoSmithKline, LLC. $23.8504/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802550497 CMS
CSL Behring $16.5803/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820235093 CMS
AstraZeneca Pharmaceuticals LP $17.5103/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829682589 CMS
GlaxoSmithKline, LLC. $16.8303/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803145807 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.3003/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763341424 CMS
GlaxoSmithKline, LLC. $1.0803/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801947451 CMS
GlaxoSmithKline, LLC. $124.9903/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803116917 CMS
GlaxoSmithKline, LLC. $0.7903/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802894511 CMS
Optinose US, Inc. $20.7402/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851658841 CMS
Regeneron Healthcare Solutions, Inc. $35.1402/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809616421 CMS
Regeneron Healthcare Solutions, Inc. $33.7901/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809616419 CMS
GlaxoSmithKline, LLC. $12.8701/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802277425 CMS
GlaxoSmithKline, LLC. $0.9401/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802454557 CMS
Amgen Inc. $16.5301/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826421319 CMS
SANOFI-AVENTIS U.S. LLC $22.7401/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843622599 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.3101/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763341426 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,796.52 72
PY2020 $910.51 51
PY2021 $2,016.05 75
PY2022 $3,596.04 109
PY2023 $4,213.66 103
PY2024 $9,207.15 104
PY2025 $10,156.49 138

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,264.60 17
PY2025 Principal investigator $155,927.91 23
PY2024 Principal investigator $41,968.94 14
PY2023 Recipient $1,377.14 10
PY2023 Principal investigator $128,088.21 37
PY2022 Principal investigator $123,394.04 35
PY2021 Principal investigator $48,220.20 10
PY2019 Principal investigator $32,822.07 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $12,860.00 12/08/2025 Non-covered Recipient Entity
Andante Research Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124745
Principal investigator 1 GlaxoSmithKline, LLC. $10,650.42 11/21/2025 Non-covered Recipient Entity
ANDANTE RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192111348
Principal investigator 1 GlaxoSmithKline, LLC. $1,482.03 10/23/2025 Non-covered Recipient Entity
ANDANTE RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192111372
Principal investigator 1 Novartis Pharmaceuticals Corporation $279.36 10/08/2025 Non-covered Recipient Entity
ANDANTE RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190313155
Principal investigator 1 GlaxoSmithKline, LLC. $7,099.29 09/24/2025 Non-covered Recipient Entity
ANDANTE RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192111353
Principal investigator 1 GlaxoSmithKline, LLC. $3,865.00 08/22/2025 Non-covered Recipient Entity
BIOGENICS RESEARCH INSTITUTE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111379
Principal investigator 1 GlaxoSmithKline, LLC. $2,940.00 08/20/2025 Non-covered Recipient Entity
ROBERT L JACOBS DBA BIOGENICS RESEARC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192172039
Principal investigator 1 GlaxoSmithKline, LLC. $2,677.00 08/20/2025 Non-covered Recipient Entity
ROBERT L JACOBS DBA BIOGENICS RESEARC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192172043
Principal investigator 1 Novartis Pharmaceuticals Corporation $320.50 08/01/2025 Non-covered Recipient Entity
ANDANTE RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190313157
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,928.41 07/29/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185543388
Principal investigator 1 GlaxoSmithKline, LLC. $42,202.71 07/18/2025 Non-covered Recipient Entity
ANDANTE RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192111366
Principal investigator 1 GENZYME CORPORATION $360.00 07/14/2025 Non-covered Recipient Entity
Andante Research Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124681
Principal investigator 1 GENZYME CORPORATION $7,766.00 07/02/2025 Non-covered Recipient Entity
Andante Research Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124684
Principal investigator 1 GlaxoSmithKline, LLC. $2,062.00 06/06/2025 Non-covered Recipient Entity
ROBERT L JACOBS DBA BIOGENICS RESEARC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192172030
Principal investigator 1 GlaxoSmithKline, LLC. $3,894.00 06/06/2025 Non-covered Recipient Entity
ROBERT L JACOBS DBA BIOGENICS RESEARC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192172034
Principal investigator 1 GENZYME CORPORATION $2,086.00 05/12/2025 Non-covered Recipient Entity
Andante Research Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124668
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,353.00 03/26/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185543386
Principal investigator 1 GENZYME CORPORATION $14,895.00 03/24/2025 Non-covered Recipient Entity
Andante Research Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124657
Recipient GlaxoSmithKline, LLC. $50.99 03/18/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192111390
Recipient GlaxoSmithKline, LLC. $10.50 03/18/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192117098
Principal investigator 1 GlaxoSmithKline, LLC. $14,308.00 03/14/2025 Non-covered Recipient Entity
ANDANTE RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192111359
Principal investigator 1 GENZYME CORPORATION $2,188.00 03/10/2025 Non-covered Recipient Entity
Andante Research Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124644
Principal investigator 1 GENZYME CORPORATION $180.00 02/04/2025 Non-covered Recipient Entity
Andante Research Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124653
Recipient GlaxoSmithKline, LLC. $293.25 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192111384
Recipient GlaxoSmithKline, LLC. $45.71 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192111397
Recipient GlaxoSmithKline, LLC. $264.84 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192117058
Recipient GlaxoSmithKline, LLC. $50.41 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192117064
Recipient GlaxoSmithKline, LLC. $293.25 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192117070
Recipient GlaxoSmithKline, LLC. $348.05 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192117076
Recipient GlaxoSmithKline, LLC. $59.81 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192117082
Recipient GlaxoSmithKline, LLC. $53.88 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192117088
Recipient GlaxoSmithKline, LLC. $46.76 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192117093
Recipient GlaxoSmithKline, LLC. $284.10 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192117104
Recipient GlaxoSmithKline, LLC. $79.69 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192117109
Recipient GlaxoSmithKline, LLC. $116.00 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192117115
Recipient GlaxoSmithKline, LLC. $124.16 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192119205
Recipient GlaxoSmithKline, LLC. $62.49 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192119211
Recipient GlaxoSmithKline, LLC. $80.71 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192119218
Principal investigator 1 GlaxoSmithKline, LLC. $1,730.00 01/10/2025 Non-covered Recipient Entity
ROBERT L JACOBS DBA BIOGENICS RESEARC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192172047
Principal investigator 1 GlaxoSmithKline, LLC. $801.19 01/10/2025 Non-covered Recipient Entity
ROBERT L JACOBS DBA BIOGENICS RESEARC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192172053